Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Study sponsor: CG Oncology, Inc. · CGON
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-03-31Estimated
Enrollment · participants325Estimated
Source updated2026-09-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.